medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2024, Number S1

<< Back Next >>

Rev Latin Infect Pediatr 2024; 37 (S1)

Consensus of the Mexican Association of Paediatric Infectious Diseases (AMIP): on the impact of vaccination on the reduction of the burden of pneumococcal disease in Mexico, 2024

González SN, Otero MFJ, Arias CCR, Becerra AAG, Chacón-Cruz E, García CLE, Jiménez JRN, Hernández MR, Hernández PM, Martínez LC, Matías JNA, Ortiz CB, Rodríguez BE, Saltigeral SP, Ortiz-Ibarra FJ

Language: Spanish
References: 67
Page: s29-49
PDF size: 508.60 Kb.


ABSTRACT

Introduction: pneumococcal disease remains a major public health concern worldwide, with invasive disease incidence documented primarily in children under two years and adults over 65. Vaccination has proven to be the most effective strategy for mitigating its impact. Material and methods: utilizing an academic consensus model, we compiled and critically reviewed the available scientific literature on current and controversial topics related to pneumococcal disease. We adhered to the guidelines outlined in the Guidelines for the Development of Consensus and the European AGREE initiative, focusing on critical reading and evaluation criteria. The recommendations are presented using the GRADE scale. The consensus involved multidisciplinary teams comprising pediatricians and pediatric infectious disease specialists affiliated with AMIP. The studies and manuscripts reviewed were selected based on keywords such as "Streptococcus pneumonia", "vaccine", "epidemiology", "vaccine safety and efficacy", and "vaccine compliance", utilizing databases including PubMed, Google Scholar, EMBASE, Cochrane, and virtual libraries from Oxford, Harvard, and Tecnológico de Monterrey. Priority was given to articles published between January 2019 and August 2024, with older references included for context or when they represented the most robust information available. The consensus process involved one in-person meeting, two virtual sessions, and external review by two independent experts. Results: ten relevant and/or controversial topics were identified and critically analyzed based on the evidence found in the included literature. The results of the critical review of the selected articles were presented with their corresponding GRADE recommendation level.


REFERENCES

  1. OPS/OMS. Neumococo. Available from: https://www.paho.org/es/temas/neumococo

  2. Pneumococcal disease. Who.int. Disponible en: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/pneumococcal-disease

  3. Ortiz-Ibarra FJ, Luévanos-Velázquez A, González SN, Reyna-Figueroa J, Chacón CE, Echaniz AG et al. Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP) sobre el impacto de la vacunación en la disminución de la carga de enfermedad neumocócica en México, 2018. Rev Latin Infect Pediatr. 2018; 31 (2): 62-75.

  4. Ferrario DC, Califano DG, Durán P, Maccarone DM, Miceli DI, Manterola A et al. Lineamientos para la elaboración de Consensos Guidelines for planning consensus Sociedad Argentina de Pediatría Subcomisiones, Comités y Grupos de Trabajo. Arch Argent Pediatr. 2012; 110 (2): 163-167. doi: 10.5546/aap.2012.163.

  5. Original AGREE instrument [Internet]. Agreetrust.org. Disponible en: https://www.agreetrust.org/resource-centre/the-original-agree-instrument/

  6. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64 (4): 383-394.

  7. Secretaria de Salud. 2021. Prevención y Control de Infecciones Respiratorias Agudas (Neumonías, Influenza y COVID-19) 2020-2024. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/706929/PAE_IRA_cF.pdf.

  8. GIVEBPVac. Datos por sexo y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Staphylococcus aureus en procesos infecciosos. 2018. Disponible en: https://www.insp.mx/resources/images/stories/Lineas/SIREVA/Docs/191115_GIVEBPVac2018_FINAL.pdf.

  9. Bardach A, Ciapponi A, Garcia-Marti S, Glujovsky D, Mazzoni A, Fayad A et al. Epidemiology of acute otitis media in children of Latin America and the Caribbean: a systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol. 2011; 75 (9): 1062-1070.

  10. Mayorga-Butrón JL, de la Torre-González C, Boronat-Echeverría N, Aguirre-Mariscal H, Montaño-Velázquez BB, Figueroa-Morales MA et al. Guía de práctica clínica para el diagnóstico y el tratamiento de la otitis media aguda en niños. Bol Med Hosp Infant Mex. 2022; 79: 1-31.

  11. Alpuche-Aranda CM, Avilez GE. Resistencia antimicrobiana y su impacto en enfermedades infecciosas en la edad pediátrica. Acta Pediátr Méx. 2024; 45 (3): 240-251.

  12. Sandoval MM, Ruvinsky S, Palermo MC, Alconada T, Brizuela ME, Wierzbicki ER et al. Antimicrobial resistance of Streptococcus pneumoniae from invasive pneumococcal diseases in Latin American countries: a systematic review and meta-analysis. Front Public Health. 2024; 12: 1337276.

  13. O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance. 2015.

  14. Comité Asesor de Vacunas de la AEP. Coadministración de las vacunas entre sí y con otros productos biológicos. Available from: https://vacunasaep.org/documentos/manual/cap-2

  15. Subramanian K, Henriques-Normark B, Normark S. Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: From nasopharyngeal colonizer to intracellular pathogen. Cell Microbiol. 2019; 21 (11): e13077.

  16. Jagne I, von Mollendorf C, Wee-Hee A, Ortika B, Satzke C, Russell FM. A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age. Vaccine. 2023; 41 (19): 3028-3037.

  17. Brizuela M, Palermo MC, Alconada T, Sandoval MM, Wierzbicki ER, Cantos J et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Latin America and the Caribbean: a systematic review and meta-analysis. PLoS One. 2024; 19 (5): e0297767.

  18. Espinosa-de los Monteros LE, Jiménez-Rojas V, Aguilar-Ituarte F, Cashat-Cruz M, Reyes-López A, Rodríguez-Suárez R et al. Streptococcus pneumoniae isolates in healthy children attending day-care centers in 12 states in Mexico. Salud Publica Mex. 2007; 49 (4): 249-255.

  19. Sosa-Delgado N, Martínez D, Lugo J, Sosa-Delgado N, Martínez D, Lugo J. Serotipos vacunales y no vacunales de Streptococcus pneumoniae en niños de Latinoamérica: revisión del último reporte SIREVA II. CES Medicina. 2020; 34 (3): 179-187.

  20. Agudelo CI, Castañeda-Orjuela C, Brandileone MC de C, Echániz-Aviles G, Almeida SCG, Carnalla-Barajas MN et al. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study. Lancet Infect Dis. 2021; 21 (3): 405-417.

  21. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018; 6 (7): e744-e757.

  22. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010; 14 (3): e197-e209.

  23. Black S, Eskola J, Whitney C, Shinefield H. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. Vaccines (Basel). 2008; 531-567.

  24. Chapman R, Sutton K, Dillon-Murphy D, Patel S, Hilton B, Farkouh R et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis. Vaccine. 2020; 38 (45): 7138-7145.

  25. Secretaría de Salud. Anuarios de Morbilidad 1984 a 2022. 2023. Disponible en: https://www.gob.mx/salud/acciones-y-programas/anuarios-de-morbilidad-1984-a-2022

  26. Valenzuela MT, O'Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A et al. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Rev Panam Salud Publica. 2009; 25 (3): 270-279.

  27. Macias-Parra M, Medina-Vera I, Arias-de la Garza E, Weber MA, León-Lara X. The impact of Haemophilus influenzae and Streptococcus pneumoniae vaccination in bacterial meningitis in a pediatric referral hospital in Mexico. J Pediatr Infect Dis. 2021; 16 (5): 230-236.

  28. PAHO. Pan American Health Organization. Technical Advisory Group on Vaccine-Preventable Diseases, editor. Final report of the 19th TAG Meeting; 2011 July 6–8; Buenos Aires, Argentina. Washington. 2011. Available in: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=14164&Itemid=&lang=fr.

  29. de Oliveira LH, Camacho LAB, Coutinho ESF, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016; 11 (12): e0166736.

  30. Carpenter AE, Hofto ME. Clinical progress note: update in management in community acquired pneumonia in children. J Hosp Med. 2023; 18 (9): 837-840.

  31. Macias-Parra M, Aguilar GM, Echaniz-Aviles G, Rionda RG, de los Ángeles-Meza-Estrada M, Cervantes Y et al. Bacterial etiology and serotypes of acute otitis media in Mexican children. Vaccine. 2011; 29 (33): 5544-5549.

  32. Guzman-Holst A, de Barros E, Rubio P, DeAntonio R, Cintra O, Abreu A. Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020. Hum Vaccin Immunother. 2022; 18 (1).

  33. Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML, Lopatynsky-Reyes EZ, Becka C, Alvelais-Palacios JA. 12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus. Therapeutic Advances in Infectious Disease. 2019; 6. doi: 10.1177/204993611983931232B

  34. Pichichero M, Kaur R, Scott D, Gruber W, Trammel J, Almudevar A et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018; 2 (8): 561-568.

  35. Dagan R, Van Der Beek BA, Ben-Shimol S, Pilishvili T, Givon-Lavi N. Effectiveness of the 7- and 13-Valent pneumococcal conjugate vaccines against vaccine-serotype otitis media. Clin Infect Dis. 2021; 73 (4): 650-658. doi: 10.1093/cid/ciab066.

  36. Levy C, Varon E, Ouldali N, Wollner A, Thollot F, Corrard F et al. Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine. PLoS One. 2019; 14 (2): e0211712. doi: 10.1371/journal.pone.0211712.

  37. Marra LP, Sartori AL, Martinez-Silveira MS, Toscano CM, Andrade AL. Effectiveness of pneumococcal vaccines on otitis media in children: a systematic review. Value Health. 2022; 25 (6): 1042-1056.

  38. Wannarong T, Ekpatanaparnich P, Boonyasiri A, Supapueng O, Vathanophas V, Tanphaichitr A et al. Efficacy of pneumococcal vaccine on otitis media: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2023; 169 (4): 765-779.

  39. Chacon-Cruz E, Lopatynsky EZ. Continuous effectiveness of pneumococcal 13-valent conjugate vaccine on pediatric pneumococcal otomastoiditis: results of 15 years of active/prospective surveillance in a Mexican Hospital on the Mexico-US Border. Cureus. 2021; 13(8): e17608.

  40. Korbal P, Wysocki J, Jackowska T, Kline M, Tamimi N, Drozd J et al. Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers. Pediatr Infect Dis J. 2024; 43 (6): 587-595.

  41. Nieto-Guevara J, Borys D, DeAntonio R, Guzman-Holst A, Hoet B. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert Rev Vaccines. 2020; 19 (11): 1011-1022.

  42. ACIP updates: recommendations for use of 20-valent pneumococcal conjugate vaccine in children - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023; 72 (39): 1072. doi: 10.15585/mmwr.mm7239a5.

  43. Álvarez-García FJ, Iofrío de Arce A, Álvarez Aldeán J, Garcés-Sánchez M, Garrote Llanos E, Montesdeoca-Melián A et al. Calendario de inmunizaciones de la Asociación Española de Pediatría: recomendaciones 2024. An Pediatr (Engl Ed). 2024; 100 (1): 34-45.

  44. Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P et al. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine. 2023; 41 (3): 657-665.

  45. Benfield T, Ramet M, Valentini P, Seppa I, Dagan R, Richmond P et al. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2). Vaccine. 2023; 41 (15): 2456-2465.

  46. Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States. Pediatr Infect Dis J. 2021; 40 (10): 944-951.

  47. AEP. Neumococo. In: Manual de inmunizaciones en línea de la AEP. 2024. Available from: http://vacunasaep.org/documentos/manual/cap-31

  48. WHO. Weekly epidemiological record. 2019. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper - February 2019.

  49. Ministerio de Salud de Argentina. Vacunación contra el neumococo, estrategia 2017-2018. Lineamientos técnicos vacuna antineumocócica conjugada de 20 serotipos en mayores de 5 años. Disponible en: https://www.argentina.gob.ar/sites/default/files/2018/02/lineamiento_tecnico_vcn20_2024.pdf

  50. Lowbridge C, McIntyre PB, Gilmour R, Chiu C, Seale H, Ferson MJ et al. Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0" schedule-How do "2+1" and "3+1" schedules compare? Vaccine. 2015; 33 (28): 3234-3241.

  51. Berman-Rosa M, O'Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145(4): e2020016568.

  52. Gabarrot GG, Vega MLP, Giffoni GPR, Ndez SH, Cardinal P, Lix VF et al. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One. 2014; 9 (11): e112337.

  53. López EL, Glatstein E, Ezcurra GC, Iacono M, Teplitz E, Garnero AV et al. Rapid decrease in rates of hospitalization resulting from invasive pneumococcal disease and community-acquired pneumonia in children aged < 60 months after 13-valent pneumococcal conjugate vaccine introduction in Argentina. J Pediatric Infect Dis Soc. 2018; 7 (1): 30-35.

  54. Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018; 67 (3): 367-374.

  55. Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014; 33 (6): 637-642.

  56. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021; 3 (6): e360-e370.

  57. Bertran M, D'Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunization schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024; 24 (5): 546-556.

  58. Ortiz-Ibarra FJ, Xóchihua DL, González SN, Chacón SJC, Luévanos VA, Otero MFJ et al. Inmunización con vacuna conjugada de neumococo y otras vacunas recomendadas en pacientes pediátricos de alto riesgo. Rev Latin Infect Pediatr. 2021; 34 (4): 162-176. doi: 10.35366/102965.

  59. van Aalst M, Lotsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A et al. Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. Travel Med Infect Dis. 2018; 24: 89-100.

  60. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011; 183 (3): 388-395.

  61. Harboe ZB, Larsen MV, Ladelund S, Kronborg G, Konradsen HB, Gerstoft J et al. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users. Clin Infect Dis. 2014; 59 (8): 1168-1176.

  62. Bliss SJ, O'Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis. 2008; 8 (1): 67-80.

  63. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical Infectious Diseases. 2014; 58 (3): 309-318.

  64. Streeter AJ, Rodgers LR, Masoli J, Lin NX, Blé A, Hamilton W et al. Real-world effectiveness of pneumococcal vaccination in older adults: cohort study using the UK Clinical Practice Research Datalink. PLoS One. 2022; 17 (10).

  65. Feldman C, Dlamini S, Richards GA, Black J, Butler ILC, Cutland C et al. A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022. J Thorac Dis. 2022; 14 (10): 4150-4172.

  66. Nakashima K, Fukushima W. Strategies for pneumococcal vaccination in older adults in the coming era. Hum Vaccin Immunother. 2024; 20 (1).

  67. Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N et al. Pneumococcal vaccine for adults aged ≥ 19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023; 72 (No. RR-3): 1-39. doi: 10.15585/mmwr.rr7203a1.




2020     |     www.medigraphic.com